IL-21 and IL-33 May Be Effective Biomarkers to Predict the Efficacy of PD-1 Monoclonal Antibody for Advanced Cholangiocarcinoma
Cancer Biotherapy and Radiopharmaceuticals · 2025
DOI: 10.1089/cbr.2024.0149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, 2025. Verfasst von Haijiao Yan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, China. Hauptthemen laut MEDLINE: Interleukins, Cholangiocarcinoma, Biomarkers, Tumor, Interleukin-33. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 77 Literaturangaben.
Abstract (Originalsprache)
Background and Objective: Treatment options for patients with advanced biliary tract cancer (BTC) are limited. The programmed cell death protein-1 (PD-1) inhibitors may have synergistic effects with chemotherapy. Therefore, the aim of our study was to provide real-world data on treatment outcomes in BTC patients receiving chemotherapy alone versus a combination of chemotherapy and PD-1 inhibitors. Additionally, we explored potential markers predictive of PD-1 inhibitor efficacy in this combined therapy.
Methods
We conducted a review of patients at Changzhou First People’s Hospital who received PD-1 inhibitors in combination with chemotherapy or chemotherapy alone as first-line treatment for advanced BTC. The primary endpoints of the study were progression-free survival (PFS) and overall survival (OS). Kaplan–Meier survival curves and the log-rank test were used to analyze the data. Immunohistochemistry showed the expression of interleukin-21 (IL-21), interleukin-33 (IL-33), and Eomes in the tumor tissue of patients who received PD-1 inhibitors in combination with chemotherapy.
Results
The study enrolled 61 patients receiving PD-1 inhibitors combined with chemotherapy and 65 receiving chemotherapy alone. The median OS and PFS for patients receiving PD-1 inhibitors in combination with chemotherapy were 11.7 and 6.7 months, respectively. These durations were significantly longer than those for chemotherapy alone: OS of 10.3 months (95% CI: 0.16–0.21, p = 0.031) and PFS of 5.3 months (95% Confidence interval (CI) 0.25–0.32, p = 0.018). High IL-21 expression or low IL-33 expression in tumor tissue correlated with better response rates to chemotherapy combined with PD-1 inhibitors.
Conclusions
Combining PD-1 inhibitors with chemotherapy shows good antitumor activity, making it an effective way to treat BTC. The expression profiles of IL-21 and IL-33 hold promise as potential markers for guiding the chemotherapy combined with immunotherapy in BTC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
- Department of Hepatobiliary Surgery, Jinshan District Central Hospital affiliated to Shanghai University of Medicine & Health Sciences, Shanghai, China.
ORCID-Profile: Wensong Liu
Zitieren
APA
Yan, H., Deng, Q., Meng, Y., Zhang, Y., Wu, J., & Liu, W. (2025). IL-21 and IL-33 May Be Effective Biomarkers to Predict the Efficacy of PD-1 Monoclonal Antibody for Advanced Cholangiocarcinoma. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2024.0149
Vancouver
Yan H, Deng Q, Meng Y, Zhang Y, Wu J, Liu W. IL-21 and IL-33 May Be Effective Biomarkers to Predict the Efficacy of PD-1 Monoclonal Antibody for Advanced Cholangiocarcinoma. Cancer Biotherapy and Radiopharmaceuticals. 2025. doi:10.1089/cbr.2024.0149
BibTeX
@article{Yan2025,
author = {Yan, Haijiao and Deng, Qian and Meng, Yu and Zhang, Ye and Wu, Jun and Liu, Wensong},
title = {IL-21 and IL-33 May Be Effective Biomarkers to Predict the Efficacy of PD-1 Monoclonal Antibody for Advanced Cholangiocarcinoma},
journal = {Cancer Biotherapy and Radiopharmaceuticals},
year = {2025},
doi = {10.1089/cbr.2024.0149}
}
EUVIMED